An innovative multimodal strategy, i.e., an approach in which specific CSC targeting drugs exert simultaneously the ability to circumvent tumor drug resistance (by ABC transporter modulation) and to exert cytotoxic activity toward CSCs and the corresponding differentiated tumor cells, may be hypothesized. This evidence concerns the gene ABCG2 and neoplasm.